Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Apr 8, 2021 → Apr 1, 2028
NCT ID
NCT04662255About Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib
Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib is a phase 3 stage product being developed by Eli Lilly for Lymphoma, Mantle-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT04662255. Target conditions include Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04662255 | Phase 3 | Active |
Competing Products
20 competing products in Lymphoma, Mantle-Cell